NASDAQ:NVUS - Novus Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.75
  • Forecasted Upside:
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Novus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVUS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$50.75
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Novus Therapeutics in the last 3 months. The average price target is $50.75, with a high forecast of $58.50 and a low forecast of $43.00. The average price target represents a ∞ upside from the last price of $0.00.
Buy
The current consensus among 2 investment analysts is to buy stock in Novus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/10/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$43.00High
i
6/2/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$10.80High
i
5/11/2020Ascendiant Capital MarketsReiterated RatingBuy ➝ Market Perform$58.50High
i
4/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$45.00High
i
11/27/2019HC WainwrightInitiated CoverageBuy$36.00High
i
Rating by V. Bernardino at HC Wainwright
8/19/2019LADENBURG THALM/SH SHReiterated RatingBuy$180.00Low
i
5/15/2019LADENBURG THALM/SH SHReiterated RatingBuy$180.00Low
i
9/11/2018LADENBURG THALM/SH SHInitiated CoverageBuy$216.00High
i
2/13/2018Ascendiant Capital MarketsInitiated CoverageBuy ➝ Buy$126.00High
i
8/24/2016BMO Capital MarketsReiterated RatingMarket Perform$30.60 ➝ $20.70N/A
i
8/10/2016William BlairReiterated RatingNeutralN/A
i
7/28/2016Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
7/26/2016BMO Capital MarketsDowngradeOutperform ➝ Market PerformN/A
i
7/26/2016William BlairDowngradeOutperform ➝ Market PerformN/A
i
Rating by Y. Xu at William Blair
7/26/2016Stifel NicolausDowngradeBuy ➝ HoldN/A
i
7/26/2016Janney Montgomery ScottDowngradeBuy ➝ NeutralN/A
i
Rating by Roy Buchanan at Janney Montgomery Scott
7/26/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
i
4/12/2016Janney Montgomery ScottReiterated RatingBuy$216.00N/A
i
Rating by Roy Buchanan at Janney Montgomery Scott
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$198.00N/A
i
4/6/2016Janney Montgomery ScottInitiated CoverageBuyN/A
i
4/6/2016Bank of AmericaInitiated CoverageBuy$288.00N/A
i
2/11/2016OppenheimerReiterated RatingOutperformN/A
i
Rating by Ling Wang at Oppenheimer Holdings Inc.
(Data available from 1/25/2016 forward)
Novus Therapeutics logo
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $16.00
$13.81
$21.30

52 Week Range

Now: N/A

Volume

1,636 shs

Average Volume

78,851 shs

Market Capitalization

$22.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Novus Therapeutics?

The following Wall Street analysts have issued reports on Novus Therapeutics in the last year: Ascendiant Capital Markets, LADENBURG THALM/SH SH, and Zacks Investment Research.

What is the current price target for Novus Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Novus Therapeutics in the last year. Their average twelve-month price target is $50.75, suggesting a possible upside of 217.4%. Ascendiant Capital Markets has the highest price target set, predicting NVUS will reach $58.50 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $43.00 for Novus Therapeutics in the next year.

What is the current consensus analyst rating for Novus Therapeutics?

Novus Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVUS will outperform the market and that investors should add to their positions of Novus Therapeutics.

What other companies compete with Novus Therapeutics?

How do I contact Novus Therapeutics' investor relations team?

Novus Therapeutics' physical mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The biopharmaceutical company's listed phone number is 949-238-8090 and its investor relations email address is [email protected] The official website for Novus Therapeutics is novustherapeutics.com.